News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
This is used to treat central diabetes insipidus and bedwetting
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Subscribe To Our Newsletter & Stay Updated
